Pharma BD Deal Intelligence

Johnson & Johnson / ALZA Corporation

2001 · Acquisition/Merger · $9.0B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Johnson & Johnson merged with ALZA Corporation in a $10.5 billion stock-for-stock transaction (0.49 J&J shares per ALZA share), acquiring a leader in controlled-release and transdermal drug delivery technologies to enhance its Janssen Pharmaceuticals unit.

Key facts

Announced Mar 26, 2001
Closed Jun 22, 2001
Deal value $9.0B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Multiple (drug delivery platform)
Key assets OROS osmotic drug delivery technology, D-TRANS transdermal system, Concerta (methylphenidate ER), Ditropan XL (oxybutynin)
Mechanism Osmotic controlled-release oral delivery, Transdermal delivery

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals